Pharnext SA
PAR:ALPHA
Pharnext SA
Other Items
Pharnext SA
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharnext SA
PAR:ALPHA
|
Other Items
€550k
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other Items
€3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Items
-€241k
|
CAGR 3-Years
58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
25%
|
|
|
Inventiva SA
PAR:IVA
|
Other Items
-€24.6m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-90%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Other Items
$584k
|
CAGR 3-Years
58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Other Items
€3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
Pharnext SA
Glance View
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Issy-Les-Moulineaux, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
See Also
What is Pharnext SA's Other Items?
Other Items
550k
EUR
Based on the financial report for Jun 30, 2023, Pharnext SA's Other Items amounts to 550k EUR.
What is Pharnext SA's Other Items growth rate?
Other Items CAGR 3Y
11%
Over the last year, the Other Items growth was 293%. The average annual Other Items growth rates for Pharnext SA have been 11% over the past three years .
